Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 comparison of VRVg-2 versus Verorab and Imovax Rabies in a simulated rabies post-exposure regimen
2018-004055-20Phase 3Completed
- Sponsor
- Sanofi
- Start
- Feb 2019
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of rabies vaccine serum-free vero cell, rabies virus inactivated antigen, A, rabies virus inactivated antigen, B and rabies immune globulin (human) in rabies (3 arms), sponsored by Sanofi. Primary endpoint: Primary: RVNA titer at least 0.5 IU/mL at Day 28. Started Feb 2019; status: completed.
02
Drugs
rabies vaccine serum-free vero cellrabies virus inactivated antigen, Arabies virus inactivated antigen, Brabies immune globulin (human)
03
Conditions
rabies
Beyond the preview
Go deeper on 2018-004055-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004055-20.